Molecular pathways: Targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2440-2444

  Ooi, Aik T ^a   Gomperts, Brigitte N ^a,b,c  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DIHYDROXY 6 METHYL 7 (PHENYLMETHYL) 4 PROPYLNAPHTHALENE 1 CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; DAPORINAD; ENZYME INHIBITOR; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; MYC PROTEIN; OXAMIC ACID; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; WZB 117; ISOENZYME; LACTATE DEHYDROGENASE 1; SLC2A1 PROTEIN, HUMAN;

AEROBIC GLYCOLYSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL ENERGY; CELLULAR DISTRIBUTION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENERGY METABOLISM; ENZYME INACTIVATION; ENZYME INHIBITION; GLYCOLYSIS; HIF1A GENE; HUMAN; LYMPHOMA; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NUCLEAR REPROGRAMMING; ONCOGENE MYC; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SLC2A1 GENE; TRANSLATIONAL RESEARCH; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MITOCHONDRION; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOGENESIS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXIDATIVE PHOSPHORYLATION;

EID: 84938418561     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1209     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
2. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
3. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27: 441-64.
4. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-70.
5. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82.
6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
7. Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 1996;16: 235-56.
8. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015-24.
9. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009;174:1544-52.
10. Wachi S, Yoneda K, Wu R. Interactome-Transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005;21:4205-8.
11. Krzeslak A, Wojcik-Krowiranda K, Forma E, Jozwiak P, Romanowicz H, Bienkiewicz A, et al. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 2012;18:721-8.
12. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, et al. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res 2014;7:487-95.
13. Koukourakis MI, Giatromanolaki A, Sivridis E. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 2003;24:199-202.
14. Balinsky D, Platz CE, Lewis JW. Isozyme patterns of normal, benign, and malignant human breast tissues. Cancer Res 1983;43:5895-901.
15. Shi M, Cui J, Du J, Wei D, Jia Z, Zhang J, et al. A novel KLF4/LDHAsignaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res 2014;20:4370-80.
16. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003;89:877-85.
17. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005;22:25-30.
18. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001;276: 43407-12.
19. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85.
20. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-21.
21. Doe MR, Ascano JM, Kaur M, Cole MD. Myc posttranscriptionally induces HIF1 protein and target gene expression in normal and cancer cells. Cancer Res 2012;72:949-57.
22. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800.
23. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z, et al. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr 2012;44:117-25.
24. Higashimura Y, Nakajima Y, Yamaji R, Harada N, Shibasaki F, Nakano Y, et al. Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells. Arch Biochem Biophys 2011;509:1-8.
25. Zawacka-Pankau J, Grinkevich VV, Hunten S, Nikulenkov F, Gluch A, Li H, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: Targeting Warburg effect to fight cancer. J Biol Chem 2011;286:41600-15.
26. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000;14:34-44.
27. Kishimoto Y, Murakami Y, ShiraishiM, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992;52:4799-804.
28. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A smallmolecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012;11:1672-82.
29. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS ONE 2011;6:e23205.
30. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007;59:495-505.
31. Wang YD, Li SJ, Liao JX. Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat 2013;12:525-35.
32. Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, Fukutake K. Lactate dehydrogenase M-subunit deficiency: A new type of hereditary exertional myopathy. Clin Chim Acta 1988;173:89-98.
33. Seth P, Grant A, Tang J, Vinogradov E, Wang X, Lenkinski R, et al. On-Target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia 2011;13:60-71.
34. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009;8:626-35.
35. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, et al. Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 2014;19:795-809.
36. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010;107: 2037-42.
37. Manerba M, Vettraino M, Fiume L, DiStefano G, Sartini A, Giacomini E, et al. Galloflavin (CAS 568-80-9): A novel inhibitor of lactate dehydrogenase. Chem Med Chem 2012;7:311-7.
38. Granchi C, Roy S, Giacomelli C, Macchia M, Tuccinardi T, Martinelli A, et al. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells. J Med Chem 2011;54:1599-612.
39. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, et al. Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes taxolresistant cancer cells to taxol. Mol Cancer 2010;9:33.
40. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011;71:4585-97.
41. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet 2013;45:104-8.
42. Kumagai S, Narasaki R, Hasumi K. Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells. Biochem Biophys Res Commun 2008;365:362-8.
43. Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC, Kim HC, et al. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. Korean J Radiol 2009;10:596-603.
44. Dwarakanath BS, Singh D, Banerji AK, Sarin R, Venkataramana NK, Jalali R, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther 2009;5 Suppl 1: S21-6.
45. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208:313-26.
46. Michelakis ED, Webster L, Mackey JR.Dichloroacetate (DCA) as a potential metabolic-Targeting therapy for cancer. Br J Cancer 2008;99:989-94.
47. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73.